Current Edition

breast cancer

Novartis, determined to dethrone Pfizer, will launch bold Kisqali-Ibrance head-to-head trial in breast cancer

Despite two life extension wins, Novartis still finds it tough to convince doctors to use its breast cancer drug Kisqali over Pfizer’s first-to-market Ibrance. Now, …

Continue Reading →